CD9 and Alzheimer disease: AEVs immunoprecipitated from AD and the control subjects carry comparable amounts of CD9, CD63, and CD81 (Figure S2), suggesting that the neurotoxicity of circulating AEVs from the AD subjects cannot be attributed to differences in general EV markers or EV concentration.